THLD has 100 million with NO DEBT, and Merck KGaA covering 70% of developmental costs. Cash burn of LESS than 2 million a quarter. 2 late stage trials for 2 major cancer indications. What more could an INVESTOR want from a developmental biotech ?
It's a very nice story. It's also nice to have cash. But remember they don't get cash for nothing. As far as the stock it gets no real respect from investors until it gets over the FDA hurdle---which is never a guarantee but looks very promising here in sarcoma & pancreatic. Investors don't care about Phase 1 stuff as its many many years from bearing any fruit----those days of investors paying for it are long gone.
Look for more days like yesterday to come where all kind of crazies come out of the woodwork.